A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)
Status
Completed
Conditions
Rheumatoid Arthritis
Details and patient eligibility
About
This is an observational study designed to follow patients with RA who have had an inadequate response to one or more anti-TNF therapies and who will receive Rituxan. Approximately 1000 patients in the United States with RA who have had an inadequate response to anti-TNF therapies and who will receive Rituxan therapy will be recruited. There is no protocol mandated treatment assignment in this study. Patients will be evaluated and treated according to their physician's standard practice and discretion.
Enrollment
1,026 patients
Sex
All
Ages
18+ years old
Volunteers
No Healthy Volunteers
Inclusion criteria
- No prior use of Rituxan (except if received within 8 weeks of screening)
- Signed Informed Consent Form
- Age ≥ 18 years
- Diagnosis of RA
- Inadequate response to one or more anti-TNF therapies
Exclusion criteria
- Have known hypersensitivity to any component of a humanized or murine monoclonal antibody
Trial contacts and locations
193
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems